Prognostic analysis of patients with pancreatic head adenocarcinoma less than 2 cm undergoing resection

Table 1 Clinicopathological features of 159 pancreatic head adenocarcinoma patients with tumor size smaller and larger than 2 cm n (%)

	S-PAC (n = 36)	L-PAC (n = 123)	P
Age (yr)	61.9 ± 8.2	62.8 ± 10.5	0.601
Sex (M/F)	22/14	74/49	0.918
Symptom (+/-)	35/1	123/0	0.226
Physical findings (+/-)	32/4	99/24	0.244
Albumin (g/dL)	3.74 ± 0.58	3.71 ± 0.61	0.827
AST (IU/L)	178.8 ± 258.5	138.1 ± 127.7	0.204
CEA (ng/mL) ≥ 5	8/27 (29.6)	33/92 (35.9)	0.549
CA 19-9 (IU/L) ≥ 37	20/29 (69.0)	72/96 (75.0)	0.518
Size (median)	1.5	3.5	0.0001
Operation time (min)	494.5 ± 141.5	469.2 ± 118.1	0.292
LN metastasis	23 (63.9)	72 (58.5)	0.565
PV invasion	4 (11.1)	12 (9.8)	0.760
Positive margin	10 (27.8)	35 (28.5)	0.244
Staging			0.459
I	12 (33.3)	39 (31.7)
II	1 (2.8)	12 (9.8)
III	22 (61.1)	71 (57.7)
IV	1 (2.8)	1 (0.8)
Tumor differentiation			0.723
W-D	11 (30.6)	38 (30.9)
M-D	19 (52.8)	59 (48.0)
P-D	6 (16.7)	26 (21.2)
Morbidity	11 (30.6)	33 (26.8)	0.660
Postoperative CT	23 (63.9)	58 (47.2)	0.077
Postoperative RT	1 (2.8)	11 (8.9)	0.300
Mortality	1 (2.8)	5 (4.1)	0.760

AST: Aspartate aminotransferase; CEA: Carcinoembryonic antigen; CA 19-9: Carbohydrate antigen 19-9; LN: Lymph node; PV: Portal vein; W-D: Well-differentiated; M-D: Moderate-differentiation; P-D: Poor-differentiation; CT: Chemotherapy; RT: Radiotherapy.